{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T22:12:26Z","timestamp":1786659146573,"version":"build-2736575974"},"reference-count":69,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T00:00:00Z","timestamp":1697500800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000070","name":"National Institute of Biomedical Imaging and Bioengineering","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000070","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"DOD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014041","name":"Alzheimer\u2019s Disease Neuroimaging Initiative","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014041","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Dementia represents a growing public health burden with large social, racial, and ethnic disparities. The etiology of dementia is poorly understood, and the lack of robust biomarkers in diverse, population-representative samples is a barrier to moving dementia research forward. Existing biomarkers and other measures of pathology\u2014derived from neuropathology, neuroimaging, and cerebrospinal fluid samples\u2014are commonly collected from predominantly White and highly educated samples drawn from academic medical centers in urban settings. Blood-based biomarkers are noninvasive and less expensive, offering promise to expand our understanding of the pathophysiology of dementia, including in participants from historically excluded groups. Although largely not yet approved by the Food and Drug Administration or used in clinical settings, blood-based biomarkers are increasingly included in epidemiologic studies on dementia. Blood-based biomarkers in epidemiologic research may allow the field to more accurately understand the multifactorial etiology and sequence of events that characterize dementia-related pathophysiological changes. As blood-based dementia biomarkers continue to be developed and incorporated into research and practice, we outline considerations for using them in dementia epidemiology, and illustrate key concepts with Alzheimer\u2019s Disease Neuroimaging Initiative (2003\u2013present) data. We focus on measurement, including both validity and reliability, and on the use of dementia blood-based biomarkers to promote equity in dementia research and cognitive aging.<\/jats:p>\n               <jats:p>This article is part of a Special Collection on Mental Health.<\/jats:p>","DOI":"10.1093\/aje\/kwad197","type":"journal-article","created":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T11:43:55Z","timestamp":1697543035000},"page":"527-535","source":"Crossref","is-referenced-by-count":21,"title":["Considerations for Use of Blood-Based Biomarkers in Epidemiologic Dementia Research"],"prefix":"10.1093","volume":"193","author":[{"given":"Eleanor","family":"Hayes-Larson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah F","family":"Ackley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indira C","family":"Turney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renaud","family":"La Joie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth Rose","family":"Mayeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M Maria","family":"Glymour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Alzheimer's Disease Neuroimaging Initiative","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,10,16]]},"reference":[{"issue":"4","key":"2024101600102715300_ref1","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/alz.12638","article-title":"2022 Alzheimer\u2019s disease facts and figures","volume":"18","author":"Alzheimer\u2019s Association","year":"2022","journal-title":"Alzheimers Dement."},{"issue":"11","key":"2024101600102715300_ref2","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1474-4422(05)70219-2","article-title":"Behavioural changes and psychological symptoms in dementia disorders","volume":"4","author":"McKeith","year":"2005","journal-title":"Lancet Neurol."},{"issue":"11","key":"2024101600102715300_ref3","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1586\/ern.11.155","article-title":"Distinguishing Alzheimer\u2019s disease from other major forms of dementia","volume":"11","author":"Karantzoulis","year":"2011","journal-title":"Expert Rev Neurother."},{"issue":"3","key":"2024101600102715300_ref4","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/1535370217750088","article-title":"Biomarker definitions and their applications","volume":"243","author":"Califf","year":"2018","journal-title":"Exp Biol Med (Maywood)."},{"issue":"3","key":"2024101600102715300_ref5","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s41582-022-00768-w","article-title":"Lecanemab trial in AD brings hope but requires greater clarity","volume":"19","author":"Thambisetty","year":"2023","journal-title":"Nat Rev Neurol."},{"issue":"16","key":"2024101600102715300_ref6","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1212\/01.wnl.0000295996.54210.69","article-title":"Disease-modifying therapies for Alzheimer disease: challenges to early intervention","volume":"69","author":"Cummings","year":"2007","journal-title":"Neurology."},{"issue":"1","key":"2024101600102715300_ref7","article-title":"On the horizon\u2014the value and promise of the global pipeline of Alzheimer\u2019s disease therapeutics","volume":"6","author":"Cole","year":"2020","journal-title":"Alzheimers Dement (N Y)."},{"issue":"3","key":"2024101600102715300_ref8","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/j.jalz.2010.06.004","article-title":"Biomarkers in Alzheimer\u2019s disease drug development","volume":"7","author":"Cummings","year":"2011","journal-title":"Alzheimers Dement."},{"issue":"2","key":"2024101600102715300_ref9","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1007\/s00415-021-10790-5","article-title":"Alzheimer\u2019s disease clinical trial update 2019\u20132021","volume":"269","author":"Pleen","year":"2022","journal-title":"J Neurol."},{"key":"2024101600102715300_ref10","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.trci.2019.05.001","article-title":"Tackling gaps in developing life-changing treatments for dementia","volume":"5","author":"Mauricio","year":"2019","journal-title":"Alzheimers Dement (N Y)."},{"key":"2024101600102715300_ref11","doi-asserted-by":"crossref","first-page":"21501319221141176","DOI":"10.1177\/21501319221141178","article-title":"Alzheimer disease biomarkers in clinical practice: a blood-based diagnostic revolution","volume":"13","author":"Paczynski","year":"2022","journal-title":"J Prim Care Community Health."},{"issue":"3","key":"2024101600102715300_ref12","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging\u2013Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement."},{"issue":"3","key":"2024101600102715300_ref13","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.neurol.2022.09.003","article-title":"Overview of the blood biomarkers in Alzheimer\u2019s disease: promises and challenges","volume":"179","author":"Delaby","year":"2023","journal-title":"Rev Neurol."},{"issue":"5","key":"2024101600102715300_ref14","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1093\/ageing\/afx090","article-title":"Circulating microRNAs as potential biomarkers for the identification of vascular dementia due to cerebral small vessel disease","volume":"46","author":"Prabhakar","year":"2017","journal-title":"Age Ageing."},{"key":"2024101600102715300_ref15","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/j.csbj.2020.06.001","article-title":"Plasma lipidomic biomarker analysis reveals distinct lipid changes in vascular dementia","volume":"18","author":"Liu","year":"2020","journal-title":"Comput Struct Biotechnol J."},{"issue":"2","key":"2024101600102715300_ref16","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.bgm.2014.11.001","article-title":"Biomarkers in vascular dementia: a recent update","volume":"7","author":"Jagtap","year":"2015","journal-title":"Biomark Genom Med."},{"issue":"6","key":"2024101600102715300_ref17","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1093\/jnen\/nlw026","article-title":"Thal amyloid stages do not significantly impact the correlation between neuropathological change and cognition in the Alzheimer disease continuum","volume":"75","author":"Serrano-Pozo","year":"2016","journal-title":"J Neuropathol Exp Neurol."},{"issue":"8","key":"2024101600102715300_ref18","doi-asserted-by":"crossref","first-page":"W163","DOI":"10.7326\/0003-4819-147-8-200710160-00010-w1","article-title":"Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration","volume":"147","author":"Vandenbroucke","year":"2007","journal-title":"Ann Intern Med."},{"issue":"1","key":"2024101600102715300_ref19","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1037\/1082-989X.7.1.19","article-title":"On the practice of dichotomization of quantitative variables","volume":"7","author":"MacCallum","year":"2002","journal-title":"Psychol Methods."},{"issue":"3","key":"2024101600102715300_ref20","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1177\/014662168300700301","article-title":"The cost of dichotomization","volume":"7","author":"Cohen","year":"1983","journal-title":"Appl Psychol Measur."},{"issue":"4","key":"2024101600102715300_ref21","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jalz.2011.04.011","article-title":"How golden is the gold standard of neuropathology in dementia?","volume":"7","author":"Scheltens","year":"2011","journal-title":"Alzheimers Dement."},{"issue":"8","key":"2024101600102715300_ref22","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/alz.12301","article-title":"Plasma p-tau181, p-tau217, and other blood-based Alzheimer\u2019s disease biomarkers in a multi-ethnic, community study","volume":"17","author":"Brickman","year":"2021","journal-title":"Alzheimers Dement."},{"issue":"5","key":"2024101600102715300_ref23","doi-asserted-by":"crossref","first-page":"e473","DOI":"10.1212\/WNL.0000000000201479","article-title":"Validity and performance of blood biomarkers for Alzheimer disease to predict dementia risk in a large clinic-based cohort","volume":"100","author":"Planche","year":"2023","journal-title":"Neurology."},{"issue":"5","key":"2024101600102715300_ref24","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/acn3.51529","article-title":"Correlation of plasma and neuroimaging biomarkers in Alzheimer\u2019s disease","volume":"9","author":"Brickman","year":"2022","journal-title":"Ann Clin Transl Neurol."},{"issue":"2","key":"2024101600102715300_ref25","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s11682-014-9297-9","article-title":"Who wants a free brain scan? Assessing and correcting for recruitment biases in a population-based sMRI pilot study","volume":"9","author":"Ganguli","year":"2015","journal-title":"Brain Imaging Behav."},{"issue":"5","key":"2024101600102715300_ref26","first-page":"e662","article-title":"Association of \u03b2-amyloid level, clinical progression, and longitudinal cognitive change in Normal older individuals","volume":"96","author":"Kall","year":"2021","journal-title":"Neurology."},{"issue":"1","key":"2024101600102715300_ref27","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/brain\/awaa399","article-title":"Time course of phosphorylated-tau181 in blood across the Alzheimer\u2019s disease spectrum","volume":"144","author":"Moscoso","year":"2021","journal-title":"Brain."},{"issue":"2","key":"2024101600102715300_ref28","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1001\/jamaneurol.2022.4485","article-title":"Association of phosphorylated tau biomarkers with amyloid positron emission tomography vs tau positron emission tomography","volume":"80","author":"Therriault","year":"2022","journal-title":"JAMA Neurol."},{"issue":"3","key":"2024101600102715300_ref29","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","article-title":"Plasma p-tau181 in Alzheimer\u2019s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia","volume":"26","author":"Janelidze","year":"2020","journal-title":"Nat Med."},{"issue":"2","key":"2024101600102715300_ref30","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","article-title":"Tracking pathophysiological processes in Alzheimer\u2019s disease: an updated hypothetical model of dynamic biomarkers","volume":"12","author":"Jack","year":"2013","journal-title":"Lancet Neurol."},{"issue":"1","key":"2024101600102715300_ref31","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1474-4422(09)70299-6","article-title":"Hypothetical model of dynamic biomarkers of the Alzheimer\u2019s pathological cascade","volume":"9","author":"Jack","year":"2010","journal-title":"Lancet Neurol."},{"issue":"1","key":"2024101600102715300_ref32","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s13195-022-01117-1","article-title":"The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer\u2019s disease: a literature review","volume":"14","author":"Brand","year":"2022","journal-title":"Alzheimers Res Ther."},{"issue":"12","key":"2024101600102715300_ref33","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201911170","article-title":"Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer\u2019s disease","volume":"11","author":"Palmqvist","year":"2019","journal-title":"EMBO Mol Med."},{"issue":"4","key":"2024101600102715300_ref34","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1002\/alz.12787","article-title":"Confounding factors of Alzheimer\u2019s disease plasma biomarkers and their impact on clinical performance","volume":"19","author":"Pichet Binette","year":"2023","journal-title":"Alzheimers Dement."},{"issue":"5","key":"2024101600102715300_ref35","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1093\/brain\/awad042","article-title":"Predicting amyloid PET and tau PET stages with plasma biomarkers","volume":"146","author":"Jack","year":"2023","journal-title":"Brain."},{"issue":"8","key":"2024101600102715300_ref36","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1093\/brain\/awy200","article-title":"Peripheral blood neurofilament light chain levels: the neurologist\u2019s C-reactive protein?","volume":"141","author":"Giovannoni","year":"2018","journal-title":"Brain."},{"issue":"1","key":"2024101600102715300_ref37","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","article-title":"Blood-based biomarkers for Alzheimer\u2019s disease: towards clinical implementation","volume":"21","author":"Teunissen","year":"2022","journal-title":"Lancet Neurol."},{"issue":"9","key":"2024101600102715300_ref38","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1093\/brain\/awab163","article-title":"Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects","volume":"144","author":"Pereira","year":"2021","journal-title":"Brain."},{"key":"2024101600102715300_ref39","first-page":"1","article-title":"Elevated levels of serum Neurofilament light chain associated with cognitive impairment in vascular dementia","volume":"2020","author":"Ma","year":"2020","journal-title":"Dis Markers."},{"issue":"4","key":"2024101600102715300_ref40","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1093\/brain\/awaa054","article-title":"Plasma tau, neurofilament light chain and amyloid-\u03b2 levels and risk of dementia; a population-based cohort study","volume":"143","author":"Wolf","year":"2020","journal-title":"Brain."},{"issue":"22","key":"2024101600102715300_ref41","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1212\/WNL.0000000000004683","article-title":"Monitoring disease activity in multiple sclerosis using serum neurofilament light protein","volume":"89","author":"Novakova","year":"2017","journal-title":"Neurology."},{"issue":"11","key":"2024101600102715300_ref42","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200861","article-title":"Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer\u2019s disease","volume":"217","author":"Barth\u00e9lemy","year":"2020","journal-title":"J Exp Med."},{"issue":"9","key":"2024101600102715300_ref43","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S1474-4422(21)00214-3","article-title":"Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer\u2019s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study","volume":"20","author":"Thijssen","year":"2021","journal-title":"Lancet Neurol."},{"issue":"2","key":"2024101600102715300_ref44","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/YCO.0000000000000851","article-title":"Plasma biomarkers for neurodegenerative disorders: ready for prime time?","volume":"36","author":"Balogun","year":"2023","journal-title":"Curr Opin Psychiatry."},{"issue":"3","key":"2024101600102715300_ref45","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/alz.12706","article-title":"Test-retest variability of plasma biomarkers in Alzheimer\u2019s disease and its effects on clinical prediction models","volume":"19","author":"Cullen","year":"2022","journal-title":"Alzheimers Dement."},{"issue":"1","key":"2024101600102715300_ref46","article-title":"Hepatic and renal function impact concentrations of plasma biomarkers of neuropathology","volume":"14","author":"Berry","year":"2022","journal-title":"Alzheimers Dement (Amst)."},{"issue":"6","key":"2024101600102715300_ref47","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/alz.12466","article-title":"Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities","volume":"18","author":"Syrjanen","year":"2022","journal-title":"Alzheimers Dement."},{"key":"2024101600102715300_ref48","doi-asserted-by":"crossref","first-page":"23","DOI":"10.26502\/anu.2644-2833058","article-title":"Kidney function impacts plasma Alzheimer\u2019s biomarkers in a cognitively Normal multi-ethnic cohort","volume":"6","author":"Hall","year":"2023","journal-title":"Arch Nephrol Urol."},{"key":"2024101600102715300_ref49","doi-asserted-by":"crossref","DOI":"10.1002\/alz.13163","article-title":"Levels of Alzheimer\u2019s disease blood biomarkers are altered after food intake-a pilot intervention study in healthy adults","author":"Huber","year":"2023","journal-title":"Alzheimers Dement."},{"issue":"10","key":"2024101600102715300_ref50","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1007\/s00259-009-1129-6","article-title":"Test-retest variability of quantitative [11C]PIB studies in Alzheimer\u2019s disease","volume":"36","author":"Tolboom","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"6","key":"2024101600102715300_ref51","doi-asserted-by":"crossref","first-page":"937","DOI":"10.2967\/jnumed.117.200691","article-title":"Test\u2013retest reproducibility for the tau PET imaging agent Flortaucipir F 18","volume":"59","author":"Devous","year":"2018","journal-title":"J Nucl Med."},{"issue":"12","key":"2024101600102715300_ref52","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1177\/0271678X19879226","article-title":"Test\u2013retest repeatability of [18F]flortaucipir PET in Alzheimer\u2019s disease and cognitively normal individuals","volume":"40","author":"Timmers","year":"2020","journal-title":"J Cereb Blood Flow Metab."},{"issue":"3","key":"2024101600102715300_ref53","doi-asserted-by":"crossref","first-page":"378","DOI":"10.2967\/jnumed.111.090340","article-title":"Performance characteristics of amyloid PET with florbetapir F 18 in patients with Alzheimer\u2019s disease and cognitively Normal subjects","volume":"53","author":"Joshi","year":"2012","journal-title":"J Nucl Med."},{"issue":"9","key":"2024101600102715300_ref54","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1001\/jamaneurol.2020.1614","article-title":"Addressing health disparities among minority populations: why clinical trial recruitment is not enough","volume":"77","author":"Wilkins","year":"2020","journal-title":"JAMA Neurol."},{"issue":"11","key":"2024101600102715300_ref55","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1093\/aje\/kwaa126","article-title":"Racial capitalism within public health-how occupational settings drive COVID-19 disparities","volume":"189","author":"McClure","year":"2020","journal-title":"Am J Epidemiol."},{"key":"2024101600102715300_ref56","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1146\/annurev-med-043021-024004","article-title":"Origins of racial and ethnic bias in pulmonary technologies","volume":"74","author":"Sjoding","year":"2023","journal-title":"Annu Rev Med."},{"issue":"4","key":"2024101600102715300_ref57","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.3233\/JAD-170840","article-title":"18F-flortaucipir binding in choroid plexus: related to race and hippocampus signal","volume":"62","author":"Lee","year":"2018","journal-title":"J Alzheimers Dis."},{"issue":"3","key":"2024101600102715300_ref58","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/01.mnh.0000444822.25991.f6","article-title":"Disparities in the burden, outcomes and care of chronic kidney disease","volume":"23","author":"Crews","year":"2014","journal-title":"Curr Opin Nephrol Hypertens."},{"issue":"2","key":"2024101600102715300_ref59","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jalz.2018.09.009","article-title":"Perspectives on ethnic and racial disparities in Alzheimer\u2019s disease and related dementias: update and areas of immediate need","volume":"15","author":"Babulal","year":"2019","journal-title":"Alzheimers Dement."},{"issue":"4","key":"2024101600102715300_ref60","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1161\/STROKEAHA.121.036140","article-title":"Blood pressure and vascular cognitive impairment","volume":"53","author":"Levine","year":"2022","journal-title":"Stroke."},{"issue":"1","key":"2024101600102715300_ref61","first-page":"4","article-title":"Racial disparities in chronic kidney diseases in the United States; a pressing public health challenge with social, behavioral and medical causes","volume":"5","author":"Assari","year":"2016","journal-title":"J Nephropharmacol."},{"key":"2024101600102715300_ref62","article-title":"Prevalence and trends of chronic kidney disease and its risk factors among US adults: an analysis of NHANES 2003\u201318","volume":"20","author":"Kibria","year":"2020","journal-title":"Prev Med Rep."},{"key":"2024101600102715300_ref63","doi-asserted-by":"crossref","DOI":"10.5888\/pcd16.180579","article-title":"Racial and ethnic disparities in adult obesity in the United States: CDC\u2019s tracking to inform state and local action","volume":"16","author":"Petersen","year":"2019","journal-title":"Prev Chronic Dis."},{"issue":"1","key":"2024101600102715300_ref64","article-title":"Biomarkers for the diagnosis of Alzheimer\u2019s disease, dementia Lewy body, frontotemporal dementia and vascular dementia","volume":"32","author":"Maclin","year":"2019","journal-title":"Gen Psychiatr."},{"issue":"1","key":"2024101600102715300_ref65","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.cger.2022.08.001","article-title":"Blood and cerebrospinal fluid biomarkers in vascular dementia and Alzheimer\u2019s disease: a brief review","volume":"39","author":"Gorelick","year":"2023","journal-title":"Clin Geriatr Med."},{"issue":"1","key":"2024101600102715300_ref66","article-title":"Comparison of plasma and CSF biomarkers across ethnoracial groups in the ADNI","volume":"14","author":"Windon","year":"2022","journal-title":"Alzheimers Dement (Amst)."},{"issue":"6","key":"2024101600102715300_ref67","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1002\/ana.25874","article-title":"Remote blood biomarkers of longitudinal cognitive outcomes in a population study","volume":"88","author":"Rajan","year":"2020","journal-title":"Ann Neurol."},{"issue":"3","key":"2024101600102715300_ref68","doi-asserted-by":"crossref","first-page":"e245","DOI":"10.1212\/WNL.0000000000200358","article-title":"Effect of race on prediction of brain amyloidosis by plasma A\u03b242\/A\u03b240, phosphorylated tau, and neurofilament light","volume":"99","author":"Schindler","year":"2022","journal-title":"Neurology."},{"issue":"1","key":"2024101600102715300_ref69","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41582-021-00589-3","article-title":"Alzheimer disease in African American individuals: increased incidence or not enough data?","volume":"18","author":"Barnes","year":"2022","journal-title":"Nat Rev Neurol."}],"container-title":["American Journal of Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/aje\/advance-article-pdf\/doi\/10.1093\/aje\/kwad197\/56618774\/kwad197.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/aje\/article-pdf\/193\/3\/527\/56865411\/kwad197.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/aje\/article-pdf\/193\/3\/527\/56865411\/kwad197.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T00:10:49Z","timestamp":1729037449000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/aje\/article\/193\/3\/527\/7319272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,16]]},"references-count":69,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,10,16]]},"published-print":{"date-parts":[[2024,3,4]]}},"URL":"https:\/\/doi.org\/10.1093\/aje\/kwad197","relation":{},"ISSN":["0002-9262","1476-6256"],"issn-type":[{"value":"0002-9262","type":"print"},{"value":"1476-6256","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,3]]},"published":{"date-parts":[[2023,10,16]]}}}